A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 166 participants.
Also called NCT06151964
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 166 participants
- Sponsor
- Registry
-
NCT06151964 -
2023-504215-32-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria, Canada, Germany, Japan, Sweden
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06151964. Randomized; triple masking; primary purpose treatment. Start 2023-09-29 (actual); primary completion 2027-01-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
- Acronym
- CONTEMPO
- Condition
- Overweight and Obesity
- Intervention (Drug)
- AZD9550
- Intervention (Drug)
- placebo
- Intervention (Drug)
- AZD9550 and AZD6234
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06151964- Content hash
1e9a97cc40fdeb0f562dd883a5957c8aa8e41f45dcebcb0afbe1c03d761200ba